NRG GU012 SAMURAI

About this trial

NRG GU012, also known as “the SAMURAI study”, is a clinical study for people with renal cell cancer that has spread beyond the kidneys, also known as metastatic renal cell cancer.
This trial is specifically for patients who are not planning on receiving surgery for their disease, or for patients not recommended to receive surgery at the time of their diagnosis. Researchers are performing this study to see if adding radiation therapy to your kidney tumour to the usual treatment of immune therapy can help stabilize your cancer or possibly cause it to shrink. The immune therapy normally prescribed for metastatic renal cell cancer consists of either two immune therapy drugs or immune therapy plus a targeted therapy drug called a VEGF inhibitor. Researchers will randomly assign patients to receive either the immune therapy treatment alone or to receive the immune therapy combined with the radiation therapy.
This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the time without cancer progressing by 6 months or more compared to the usual approach.

Patient Profile

Pathologically (histologically or cytologically) proven diagnosis of renal cell carcinoma

Where’s this trial being run?

Beacon Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

Print this page

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	NRG GU012 SAMURAI
Number:	22-17
Full Title:	RANDOMIZED PHASE II STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR) FOR METASTATIC UNRESECTED RENAL CELL CARCINOMA (RCC) RECEIVING IMMUNOTHERAPY.

Principal Investigator:	Prof Alina Mihaela Mihai
Type:	Collaborative
Sponsor:	NRG
Recruitment Started:	Global: Ireland: Recruitment started at Beacon Site

Global Recruitment Target:	240
Ireland Recruitment Target:	27